Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia

Journal of Nuclear Medicine

Volumn 40, Issue 6, 1999, Pages 1072-1079

  Rasey, Janet S ^a,b   Hofstrand, Philip D ^a   Chin, Lay K ^a   Tewson, Timothy J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

18F fluoroetanidazole; 18F fluoromisonidazole; Hypoxia; Tumor imaging

Indexed keywords

ETANIDAZOLE; FLUORINE 18; FLUOROETANIDAZOLE F 18; UNCLASSIFIED DRUG; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; FLUOROETANIDAZOLE; MISONIDAZOLE; OXYGEN; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG UPTAKE; HYPOXIA; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; ANIMAL; BINDING SITE; C3H MOUSE; CELL CULTURE; CELL HYPOXIA; CRICETULUS; CYTOLOGY; EXPERIMENTAL NEOPLASM; FEMALE; FIBROBLAST; FIBROSARCOMA; GLIOMA; HAMSTER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LUNG; MALE; METABOLISM; SARCOMA; SCINTISCANNING; TIME;

ANIMALS; BINDING SITES; BLOOD-BRAIN BARRIER; CELL HYPOXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRAST MEDIA; CRICETINAE; CRICETULUS; ETANIDAZOLE; FEMALE; FIBROBLASTS; FIBROSARCOMA; FLUORINE RADIOISOTOPES; GLIOMA; LUNG; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; MISONIDAZOLE; NEOPLASMS, EXPERIMENTAL; OXYGEN; RADIOPHARMACEUTICALS; RATS; SARCOMA, EXPERIMENTAL; TIME FACTORS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0032587188     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Mottram J. Factor of importance in radiotherapy of tumours. Br J Radiol. 1936;9:606-614.
2. Gray LH, Conger AD, Ebert M, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:628-654.
3. Höckel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509-4515.
4. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56:941-943.
5. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [F-18]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
6. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
7. Grierson JR, Mathis CA, Rasey JS, Krohn KA. A radiosynthesis of [F-18]fluoromisonidazole. J Nucl Med. 1989;30:343-350.
8. Valk PE, Mathis CA, Prados MD, et al. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133-2137.
9. Yeh SH, Liu RS, Wu LC, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngea carcinoma. Eur J Nucl Med. 1996;23:1378-1383.
10. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995;22:265-280.
11. Tewson T. Synthesis of [F-18]fluoroetanidazole: a potential new tracer for imaging hypoxia. Nucl Med Biol. 1997;24:755-760.
12. Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 1993;53:90-95.
13. Koch C, Evans S, Lord E. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imadazol-1-yl)-N-(2,2,3,3,3-pertafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs. bound radioactivity. Br J Cancer. 1995;72:865-870
14. Koch CJ. The reduction activation of nitroimidazoles; modification by oxygen and other redox-active molecules in cellular systems. In: Adams GE, ed. Selective Activation of Drugs by Redox Processes. New York, NY: Plenum Press; 1990:237-247.
15. Koch CJ. A thin-film culturing technique allowing rapid gas-liquid equilibration (6 sec) with no toxicity to mammalian cells. Radiat Res. 1984;97:434-442.
16. Rasey JS, Nelson NJ, Chin L, et al. Characterization of the binding of labeled fluoromisonidazole in cells in vitro. Radial Res, 1990;122:301-308.
17. Brown JM, Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res. 1980;82:171-190.
18. Adams GE, Clarke ED, Gray P, et al. Structure-activity relationships in the development of hypoxic cell radiosensitizers, II. Cytotoxicity and therapeutic ratio. Int J Radiat Biol Relat Stud Phys Chem Med. 1979;35:151-160.
19. Workman P. Pharmacokinetics of hypoxic cell radiosensitizers. In: Brady L, ed. Radiation Sensitizer: Their Use in the Clinical Management of Cancer. New York, NY: Massion Publishing USA, Inc.; 1980:192-206.
20. 3H-labelled misonidazole in the tumor-bearing mouse. Int J Radiat Oncol Biol Phys. 1990;18:347-351.
21. Leith JT, Michelson S. Secretion rates and levels of vascular endothelial growth factor in clone A or HCT-8 human colon tumour cells as a function of oxygen concentration. Cell Proliferation. 1995;28:415-430.
22. Rasey JS, Wilson DC, Chin L, Hofstrand P. Oxygen dependency of VEGF induction in tumor cells and its relation to severe hypoxia in human sarcomas [abstract]. Im J Radial Oncol Biol Phys. 1998;42(suppl):230.
23. Kennedy KA, Teicher BA, Rockwell S, Sartorelli AC. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol. 1980;29: 1-8.